Background: In the last decade, a number of new treatment modalities have been developed for patients with small cell lung cancer (SCLC). The clinical effects are encouraging, but little is known about the costs and cost-effectiveness of new drugs. Methods: A Markov chain model has been developed to project patient outcomes and costs for patients with advanced SCLC. All patients in the control ...

background research predicting the public health and fiscal impact of supervised injection facilities (sifs), across different cities in canada, has reported positive results on the reduction of hiv cases among people who inject drugs (pwid). most of the existing studies have focused on the outcomes of insite, located in the vancouver downtown eastside (dtes). previous attention has not been af...

abstract background: primary immunodeficiency diseases (pid) are heterogeneous group of inherited disorders mainly characterized by recurrent infections leading to several times hospital admissions. the economic impact of pid is a challenging issue; therefore, this study was designed to determine the medical costs of hospitalizations in this group of patients as an indicator of the direct cost ...

Background Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some e...

This paper examines the issue of prices, relative to value, for cancer drugs. The analysis focuses on the effects on manufacturer pricing incentives of insurance coverage, specifically, the effectiveness of patient cost sharing, incentives created by reimbursement rules for physician-dispensed drugs, and payer ability and incentives to negotiate discounts. For pharmacy-dispensed cancer drugs, b...